137 related articles for article (PubMed ID: 34008498)
1. Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Non-Small Cell Lung Cancer.
Tuminello S; Petralia F; Veluswamy R; Wang P; Flores R; Taioli E
Am J Clin Oncol; 2021 Jul; 44(7):350-355. PubMed ID: 34008498
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
3. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients.
Li X; Li X; Fu X; Liu L; Liu Y; Zhao H; Li Y; Hu J; Xu L; Liu D; Yang H; Zhang X
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1874-1881. PubMed ID: 31902592
[TBL] [Abstract][Full Text] [Related]
7. Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
Grosu HB; Manzanera A; Shivakumar S; Sun S; Noguras Gonzalez G; Ost DE
Lung Cancer; 2020 Feb; 140():55-58. PubMed ID: 31865279
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
9. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
10. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
[TBL] [Abstract][Full Text] [Related]
13. Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival.
Shin DW; Cho JH; Yoo JE; Cho J; Yoon DW; Lee G; Shin S; Kim HK; Choi YS; Kim J; Zo JI; Shim YM
Cancer Res Treat; 2021 Oct; 53(4):1057-1071. PubMed ID: 33705624
[TBL] [Abstract][Full Text] [Related]
14. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.
Kadota K; Nitadori JI; Ujiie H; Buitrago DH; Woo KM; Sima CS; Travis WD; Jones DR; Adusumilli PS
J Thorac Oncol; 2015 Sep; 10(9):1301-1310. PubMed ID: 26291010
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer.
Duarte IG; Bufkin BL; Pennington MF; Gal AA; Cohen C; Kosinski AS; Mansour KA; Miller JI
J Thorac Cardiovasc Surg; 1998 Mar; 115(3):652-8; discussion 658-9. PubMed ID: 9535454
[TBL] [Abstract][Full Text] [Related]
17. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
18. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.
Chansky K; Sculier JP; Crowley JJ; Giroux D; Van Meerbeeck J; Goldstraw P;
J Thorac Oncol; 2009 Jul; 4(7):792-801. PubMed ID: 19458556
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
Giatromanolaki A; Anestopoulos I; Panayiotidis MI; Mitrakas A; Pappa A; Koukourakis MI
Anticancer Res; 2021 Aug; 41(8):3989-3995. PubMed ID: 34281863
[TBL] [Abstract][Full Text] [Related]
20. A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm.
Blaauwgeers H; Damhuis R; Lissenberg-Witte BI; de Langen AJ; Senan S; Thunnissen E
J Thorac Oncol; 2019 Mar; 14(3):459-467. PubMed ID: 30408568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
